

IAP13 Receipt Dated 12 DEC 2005

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

10/17/0281

Application Number	10/17/0281
Filing Date	December 12, 2005
First Named Inventor	Kazutaka TACHIBANA
Group Art Unit	
Examiner Name	

Attorney Docket Number TACHIBANA1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KC	AA	US-5411981	05/02/1995	GAILLARD-KELLY et al.	
KC	AB	US-5627201	05/06/1997	GAILLARD-KELLY et al.	
KC	AC	US-35,956	11/10/1998	GAILLARD-KELLY et al.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
KC	AD	GB 2118942 A1	04/27/1982	CIBA-GEIGY AG		
KC	AE	JP 02-528434 S	09/03/2002	DOMPE' S.P.A.		
KC	AF	JP 10-510845 A	10/20/1998	BIOPHYSICA FOUNDATION		
KC	AG	JP 4-308579 A	10/30/1992	ROUSSEL UCLAF		
KC	AH	JP 58-194891 A	11/12/1983	CIBA-Geigy AG		
KC	AI	JP 6-73017 A	03/15/1994	ROUSSEL UCLAF		
KC	AJ	WO 00/24710	05/04/2000	DOMPE' S.P.A.		
KC	AK	WO 97/00071	01/03/1997	BIOPHYSICA FOUNDATION		
KC	AL	EP 580459 A1	01/26/1994	ROUSSEL-UCLAF		
KC	AM	EP 0494819 A1	07/15/1992	ROUSSEL-UCLAF		
KC	AN	WO 03/093243 A1	11/13/2003	AVENTIS PHARMA DEUTSCHLAND GMBH		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KC	AO	WONG, Choi-ik, "Androgen Receptor Antagonist versus Agonist Activities of the Fungicide Vinclozolin Relative to Hydroxyflutamide", vol. 270, no. 34, pp. 19998-20003, 1995	

Examiner
Signature

/Karen Cheng/

Date
Considered

01/05/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.